Association of risk of clinical recurrence (CR) and prostate cancer death (PCD) with a 17-gene genomic prostate score (GPS) value <20.

被引：0
|
作者：
Febbo, Phillip G.
Crager, Michael
Burke, Emily
Lawrence, H. Jeffrey
Cullen, Jennifer
Klein, Eric A.
机构：
[1] Genom Hlth, Redwood City, CA USA
[2] Ctr Prostate Dis Res, Rockville, MD USA
[3] Glickman Urol & Kidney Inst, Cleveland, OH USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.5074
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5074
引用
收藏
页数：5
相关论文
共 45 条
  • [1] A 17-gene genomic prostate score (GPS) as a predictor of biochemical (BCR) and clinical recurrence (CR) in men with surgically treated intermediate- and high-risk prostate cancer (PCa).
    Klein, Eric A.
    Zhang, Nan
    Crager, Michael
    Maddala, Tara
    Febbo, Phillip G.
    Thomas, Shibu
    Gormley, Michael
    Ricci, Deborah Sokol
    Falzarano, Sara Moscovita
    Magi-Galluzzi, Cristina
    Lawrence, H. Jeffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [2] A 17-gene genomic prostate score (GPS) as a predictor of biochemical (BCR) and clinical recurrence (CR) in men with surgically treated intermediate- and high-risk prostate cancer (PCa).
    Klein, Eric A.
    Brand, Timothy
    Rosner, Inger L.
    Zhang, Nan
    Crager, Michael
    Maddala, Tara
    Febbo, Phillip G.
    Thomas, Shibu
    Gormley, Michael
    Ricci, Deborah S.
    Falzarano, Sara Moscovita
    Magi-Galluzzi, Cristina
    Cullen, Jennifer
    Sesterhenn, Isabel
    Lawrence, H. Jeffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [3] The 17-gene Genomic Prostate Score assay as a predictor of biochemical recurrence in men with intermediate and high-risk prostate cancer
    Helfand, Brian T.
    Paterakos, Michael
    Wang, Chi-Hsiung
    Talaty, Pooja
    Abranid, John
    Bennett, John
    Hallid, David W.
    Lehman, Amy
    Aboushwareb, Tamer
    PLOS ONE, 2022, 17 (09):
  • [4] Clinical utility of a 17-gene genomic prostate score (GPS) for treatment selection in men with newly diagnosed prostate cancer (PCa).
    Dall'Era, Marc A.
    Denes, Bela
    Lawrence, H. Jeffrey
    Tsiatis, Athanasios C.
    Rothney, Megan
    Maddala, Tara
    Febbo, Phillip G.
    Badani, Ketan
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [5] The 17-gene Genomic Prostate Score® assay as a predictor of biochemical recurrence in men with intermediate- and high-risk prostate cancer
    Helfand, B. T.
    Paterakos, M.
    Wang, C-H.
    Talaty, P.
    Abran, J.
    Bennett, J. P.
    Hall, D. W.
    Aboushwareb, T.
    EUROPEAN UROLOGY, 2021, 79 : S1709 - S1710
  • [6] BIOMARKERS OF BIOCHEMICAL (BCR) AND CLINICAL RECURRENCE (CR) IN PROSTATE CANCER (PCA) FOLLOWING RADICAL PROSTATECTOMY (RP) - PERFORMANCE OF A 17-GENE GENOMIC PROSTATE SCORE (GPS) AND TESTS FOR PTEN LOSS.
    Magi-Galluzzi, Cristina
    Bonham, Michael
    Tsiatis, Athanasios
    Falzarano, Sara
    Dee, Anne
    Maddala, Tara
    Knezevic, Dejan
    Febbo, Phillip
    Lawrence, H. Jeffrey
    Klein, Eric
    JOURNAL OF UROLOGY, 2016, 195 (04): : E18 - E18
  • [7] Association between a 17-gene genomic prostate score and multiparametric prostate MRI in men with low- and intermediate-risk prostate cancer (PCa).
    Leapman, Michael S.
    Westphalen, Antonio C.
    Ameli, Niloufar
    Lawrence, H. Jeffrey
    Febbo, Phillip G.
    Cooperberg, Matthew R.
    Carroll, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [8] The 17-Gene Genomic Prostate Score Test as a Predictor of Outcomes in Men with Unfavorable Intermediate Risk Prostate Cancer
    Cullen, Jennifer
    Kuo, Huai-Ching
    Shan, Jun
    Lu, Ruixiao
    Aboushwareb, Tamer
    Eeden, Stephen K. Van Den
    UROLOGY, 2020, 143 : 103 - 111
  • [9] Prognostic value of 17-Gene genomic prostate score in patients with clinically localized prostate cancer: a meta-analysis
    Cui, Feilun
    Tang, Xuan
    Man, Changfeng
    Fan, Yu
    BMC CANCER, 2024, 24 (01)
  • [10] Association between a 17-gene genomic prostate score and multi-parametric prostate MRI in men with low and intermediate risk prostate cancer (PCa)
    Leapman, Michael S.
    Westphalen, Antonio C.
    Ameli, Niloufar
    Lawrence, H. Jeffrey
    Febbo, Phillip G.
    Cooperberg, Matthew R.
    Carroll, Peter R.
    PLOS ONE, 2017, 12 (10):
12345